参考文献:[1]He HJ, et al. [Analysis of Clinical Features and Prognosis in 31 Patients with Primary Myelofibrosis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Dec;23(6):1721-8. Chinese. doi: 10.7534/j.issn.1009-2137.2015.06.035.[2]Vannucchi AM,et al; COMFORT Investigators. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015 Sep;100(9):1139-45. doi:10.3324/haematol.2014.119545. Epub 2015 Jun 11.[3]Song MK,et al. Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis. Int J Hematol. 2016 Oct;104(4):476-84. doi:10.1007/s12185-016-2050-y. Epub 2016 Jun 27.[4]Mesa RA,et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica. 2014 Feb;99(2):292-8. doi:10.3324/haematol.2013.087650. Epub 2013 Aug 2.[5]Linguraru MG, et al. Assessing splenomegaly:automated volumetric analysis of the spleen. Acad Radiol. 2013 Jun;20(6):675-84. doi:10.1016/j.acra.2013.01.011. Epub 2013 Mar 25.[6]中华医学会血液学分会白血病淋巴瘤学组.原发性骨髓纤维化诊断与治疗中国指南(2019年版)[J].中华血液学杂志,2019,40(1):7.DOI:10.3760/cma.j.issn.0253-2727.2019.01.001.[7]CSCO恶性血液病指南(2024年)版